Visipaque: Uses, Dosage & Side Effects
An iso-osmolar, non-ionic iodinated contrast agent used to enhance diagnostic imaging including CT scans, angiography, myelography and urography
Visipaque (iodixanol) is a prescription iodinated contrast agent used to improve the visualization of internal body structures during diagnostic imaging procedures such as CT scans, angiography, urography, and myelography. It is the only commercially available iso-osmolar contrast medium (IOCM), meaning its osmolality matches that of blood. Visipaque is administered by healthcare professionals in clinical settings via intravenous, intra-arterial, intrathecal, or oral routes depending on the procedure. Its iso-osmolar properties are associated with better patient comfort during injection and a favorable safety profile, particularly in patients at increased risk of contrast-induced nephropathy.
Quick Facts: Visipaque
Key Takeaways
- Visipaque (iodixanol) is the only iso-osmolar contrast medium (IOCM) available, with an osmolality equal to blood (~290 mOsm/kg), which reduces discomfort during injection and may lower the risk of contrast-induced nephropathy in high-risk patients.
- It is used in a wide range of diagnostic imaging procedures including CT scans, coronary and peripheral angiography, urography, myelography, arthrography, and gastrointestinal studies.
- Available in two iodine concentrations (270 mg I/mL and 320 mg I/mL), the dosage and route of administration depend on the specific procedure and the patient’s age, weight, and kidney function.
- The most common side effects are a transient sensation of warmth, headache, and nausea; serious allergic reactions are uncommon but possible, and emergency equipment should always be available during administration.
- Patients with kidney disease, diabetes (especially those taking metformin), thyroid disorders, or a history of contrast media reactions require special precautions and monitoring before and after the procedure.
What Is Visipaque and What Is It Used For?
Visipaque contains the active substance iodixanol, a non-ionic, dimeric, water-soluble iodinated contrast medium designed specifically for use in diagnostic radiology. Each molecule of iodixanol contains six iodine atoms, which give the compound its X-ray absorbing properties. When injected into a blood vessel or administered into a body cavity, iodixanol increases the radiodensity (X-ray absorption) of the area where it distributes, creating contrast between different anatomical structures that would otherwise appear similar on plain radiographs or CT images.
What makes Visipaque unique among all commercially available iodinated contrast agents is its iso-osmolar formulation. Osmolality refers to the concentration of dissolved particles in a solution. Blood has an osmolality of approximately 290 mOsm/kg. Most iodinated contrast agents are hyperosmolar, meaning they have an osmolality higher than blood. Visipaque, however, is formulated to have an osmolality equal to that of blood in both its 270 mg I/mL and 320 mg I/mL concentrations. This is achieved through iodixanol’s dimeric molecular structure, which delivers a high iodine payload per molecule while maintaining physiological osmolality. The iso-osmolar property reduces the osmotic stress on cells and tissues during injection, resulting in less pain at the injection site, fewer hemodynamic disturbances, and potentially reduced risk of organ damage, particularly in the kidneys.
Visipaque is classified as a diagnostic agent and is used exclusively for diagnostic purposes. It does not treat or cure any medical condition. Instead, it serves as a tool to help your doctor see internal body structures more clearly on imaging studies, enabling more accurate diagnosis. Your doctor will explain which part of your body will be examined and why contrast enhancement is necessary for your particular investigation.
Indications and Clinical Uses
Visipaque is approved for use in a wide range of diagnostic imaging procedures. The specific applications depend on the route of administration:
- Computed Tomography (CT) Scanning: Visipaque is injected intravenously before or during CT scans of the head, chest, abdomen, pelvis, and extremities. Contrast-enhanced CT provides significantly improved visualization of tumors, infections, vascular abnormalities, and organ pathology compared with non-contrast CT. This is one of the most common uses of Visipaque worldwide.
- Angiography: When injected into arteries or veins via a catheter, Visipaque enables visualization of the vascular system. This includes coronary angiography (imaging of the heart’s blood vessels), cerebral angiography (brain vessels), peripheral angiography (limb vessels), and venography (veins). Coronary angiography with iodinated contrast remains the gold standard for diagnosing coronary artery disease.
- Urography: After intravenous injection, Visipaque is filtered by the kidneys and concentrated in the urinary tract, allowing visualization of the kidneys, ureters, and bladder. This technique helps diagnose kidney stones, tumors, structural abnormalities, and obstructions in the urinary system.
- Myelography: Visipaque can be injected into the subarachnoid space (the area around the spinal cord) to visualize the spinal canal and nerve roots. This is particularly useful for diagnosing spinal cord compression, herniated discs, and other spinal abnormalities, especially when MRI is contraindicated or unavailable.
- Arthrography: Injection of Visipaque directly into a joint (such as the knee, shoulder, or hip) allows detailed imaging of the joint cavity, cartilage, ligaments, and surrounding soft tissues.
- Hysterosalpingography: Visipaque can be instilled into the uterus and fallopian tubes to assess tubal patency and uterine abnormalities, often as part of a fertility evaluation.
- Gastrointestinal Studies: When given orally, Visipaque can be used to examine the esophagus, stomach, and small intestine. This is particularly useful in patients where barium-based contrast agents are contraindicated, such as when there is a suspected perforation of the gastrointestinal tract.
The iso-osmolar property of Visipaque means that when injected into the bloodstream, it does not draw water out of red blood cells or surrounding tissues (as hyperosmolar agents can). This results in less deformation of red blood cells, less endothelial cell damage, less disruption of the blood-brain barrier, and reduced sensation of heat or pain during injection. For patients undergoing coronary angiography or those with impaired kidney function, these properties may translate into clinically meaningful safety advantages.
What Should You Know Before Receiving Visipaque?
Contraindications
Visipaque must not be administered in the following situations:
- Severe thyrotoxicosis: Patients with uncontrolled overactive thyroid (hyperthyroidism or thyrotoxicosis) should not receive Visipaque. The iodine in the contrast agent can be taken up by the thyroid gland and worsen thyroid overactivity, potentially precipitating a thyroid storm, which is a life-threatening emergency.
- Known hypersensitivity: Patients with a documented severe allergic reaction (anaphylaxis) to iodixanol or any of the excipients in the formulation should not receive Visipaque. Excipients include trometamol (tromethamine), sodium chloride, calcium chloride dihydrate, sodium calcium edetate, hydrochloric acid (for pH adjustment), and water for injections.
Warnings and Precautions
Allergic-like reactions to iodinated contrast media can range from mild (skin rash, hives) to life-threatening (anaphylaxis with cardiovascular collapse and respiratory failure). These reactions can occur immediately during injection or may be delayed by hours or even days. All healthcare facilities administering Visipaque must have emergency resuscitation equipment and personnel trained in managing anaphylaxis readily available.
Inform your doctor before receiving Visipaque if any of the following apply to you:
- Previous contrast media reaction: Patients who have previously experienced an allergic reaction to any iodinated contrast agent are at significantly increased risk (5–6 times higher) of having another reaction. Your doctor may decide to premedicate you with corticosteroids and antihistamines before the procedure, or may choose an alternative imaging method.
- Asthma or allergies: Patients with active asthma or a history of significant allergies (including hay fever, food allergies, or eczema) are at increased risk of contrast media reactions. An asthma attack can be triggered by contrast administration.
- Kidney disease: All iodinated contrast agents are excreted by the kidneys and can cause contrast-induced nephropathy (CIN), also known as post-contrast acute kidney injury (PC-AKI). Patients with pre-existing kidney disease, particularly those with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m², are at the highest risk. Adequate hydration before and after the procedure is essential to minimize kidney damage. Your doctor should check your kidney function (serum creatinine and eGFR) before administering Visipaque.
- Diabetes: Patients with diabetes, particularly those with diabetic nephropathy, are at increased risk of contrast-induced kidney injury. Additionally, patients taking the diabetes medication metformin require special attention (see Drug Interactions section).
- Heart or lung disease: Patients with severe heart failure, pulmonary hypertension, or other significant cardiovascular conditions may be at increased risk of hemodynamic complications during contrast administration. Intra-arterial injection of contrast media introduces a large volume of fluid into the circulation, which can exacerbate heart failure.
- Epilepsy or neurological conditions: Patients with epilepsy, a history of stroke, brain tumors, or other conditions that lower the seizure threshold should be monitored carefully, as contrast media may rarely provoke seizures, particularly when administered intrathecally.
- Myasthenia gravis: Iodinated contrast agents may temporarily worsen the symptoms of myasthenia gravis, a condition causing severe muscle weakness.
- Pheochromocytoma: Patients with pheochromocytoma (a rare adrenal gland tumor causing high blood pressure) are at risk of a hypertensive crisis during contrast administration. Alpha-blocker pretreatment should be considered.
- Thyroid disorders: Even in patients without overt thyroid disease, the iodine load from contrast media can affect thyroid function. Patients scheduled for thyroid function tests within the following weeks should inform their doctor, as Visipaque can interfere with test results for several weeks. Patients with multinodular goiter or subclinical hyperthyroidism may develop contrast-induced thyrotoxicosis.
- Paraproteinemia: Patients with multiple myeloma or other conditions causing elevated protein levels in the blood are at increased risk of kidney injury from contrast media due to precipitation of proteins in the renal tubules.
- Alcohol or substance dependence: Active alcohol or substance dependence may increase the risk of seizures during or after contrast administration.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, inform your doctor before the procedure. The safety of Visipaque in pregnant women has not been established through adequate clinical trials. Iodinated contrast agents are known to cross the placenta and may affect the fetal thyroid gland due to their iodine content. Visipaque should only be administered during pregnancy if your doctor determines that the benefit of the diagnostic procedure clearly outweighs the potential risk to you and your unborn child. If Visipaque is administered during pregnancy, the newborn’s thyroid function should be monitored during the first week of life, as transient neonatal hypothyroidism has been reported following in utero exposure to iodinated contrast media.
The amount of Visipaque excreted into breast milk is very small, and the amount that would be absorbed from the infant’s gastrointestinal tract is negligible. Both the American College of Radiology (ACR) and the European Society of Urogenital Radiology (ESUR) have concluded that breastfeeding does not need to be interrupted after administration of iodinated contrast media. You may continue breastfeeding as normal after receiving Visipaque.
Driving and Operating Machinery
If you have received Visipaque via intrathecal injection (into the spinal canal), you should not drive or operate machinery for 24 hours after the procedure. For other routes of administration (intravenous, intra-arterial), Visipaque is not expected to affect your ability to drive. However, you should take into account the effects of the underlying medical condition being investigated and any other medications you may have received during the procedure (such as sedatives). If you experience any symptoms that could impair your driving ability (such as dizziness, visual disturbances, or drowsiness), refrain from driving until these have resolved.
How Does Visipaque Interact with Other Drugs?
Although Visipaque is not metabolized by the liver and does not undergo cytochrome P450-mediated biotransformation, there are several clinically important drug interactions that healthcare professionals and patients should be aware of. These interactions are primarily related to the physiological effects of the contrast agent on kidney function, thyroid function, and the cardiovascular system, rather than pharmacokinetic drug-drug interactions in the traditional sense.
| Medication | Interaction | Recommendation |
|---|---|---|
| Metformin | Contrast-induced kidney injury can impair metformin excretion, leading to metformin accumulation and potentially fatal lactic acidosis | In patients with eGFR <30: stop metformin 48h before and do not restart until kidney function is confirmed stable. In patients with eGFR 30–60: follow local guidelines; reassess kidney function 48h after contrast. |
| Interleukin-2 | Recent treatment with interleukin-2 (within 2 weeks) significantly increases the risk of delayed allergic-like reactions to contrast media | Inform your radiologist if you have received interleukin-2 within 2 weeks before the procedure. Premedication and extended monitoring may be necessary. |
| Beta-blockers | Beta-blockers may mask the early cardiovascular signs of anaphylaxis (tachycardia) and reduce the effectiveness of epinephrine (adrenaline) used to treat severe allergic reactions | Patients on beta-blockers who develop anaphylaxis may require higher doses of epinephrine and additional glucagon. Extra vigilance is needed. |
| Nephrotoxic drugs | Concurrent use of nephrotoxic medications (aminoglycosides, NSAIDs, ciclosporin, tacrolimus) may increase the risk of contrast-induced kidney injury | Where possible, discontinue nephrotoxic medications before contrast administration and ensure adequate hydration. |
| Radioactive iodine therapy | The iodine load from Visipaque saturates the thyroid, reducing uptake of radioactive iodine for weeks afterward | If radioactive iodine therapy or thyroid scintigraphy is planned, delay Visipaque administration or allow a washout period of several weeks. |
Metformin and Contrast Media
The interaction between metformin and iodinated contrast media is one of the most clinically important considerations in modern radiology practice. Metformin itself does not directly interact with contrast agents. However, if contrast administration causes even mild kidney injury (which may be subclinical), the impaired kidneys cannot excrete metformin efficiently. This leads to metformin accumulation in the blood, which can cause lactic acidosis—a rare but potentially fatal metabolic emergency with a mortality rate of approximately 50% when severe.
Current guidelines from the ACR, ESUR, and the Royal College of Radiologists provide risk-stratified recommendations. Patients with normal kidney function (eGFR ≥60 mL/min/1.73 m²) can generally continue metformin without interruption. Patients with moderate kidney impairment (eGFR 30–59) should have their kidney function reassessed 48 hours after contrast administration before restarting metformin. Patients with severe kidney impairment (eGFR <30) should stop metformin 48 hours before the procedure and not restart until kidney function is confirmed to be stable.
Effects on Laboratory Tests
Visipaque can interfere with several laboratory test results if blood or urine samples are collected on the same day as the procedure. The iodine in the contrast agent may affect thyroid function tests (TSH, T3, T4), and the high protein content of the urine after contrast excretion can cause false-positive results on urine protein tests. Blood samples for coagulation studies and certain biochemical analyses may also be affected. Inform your doctor or the laboratory if you have recently received contrast media.
The single most important protective measure against contrast-induced kidney injury is adequate hydration. Patients should drink plenty of fluids before and after the procedure (unless fluid restriction is medically necessary). In high-risk patients, intravenous hydration with normal saline before and after contrast administration is the standard of care. Studies have consistently shown that proper hydration significantly reduces the incidence of post-contrast acute kidney injury.
What Is the Correct Dosage of Visipaque?
Unlike most medications that have fixed doses, the dosage of Visipaque is highly individualized and depends on the specific imaging procedure being performed, the anatomical region being examined, the route of administration, and patient-specific factors such as body weight, age, cardiac output, and kidney function. Your radiologist or the healthcare professional performing the procedure will determine the appropriate dose for you.
Adults – Intravenous and Intra-arterial Administration
| Procedure | Concentration | Typical Volume Range |
|---|---|---|
| CT – Head | 270 or 320 mg I/mL | 50–150 mL |
| CT – Body (chest/abdomen/pelvis) | 270 or 320 mg I/mL | 75–200 mL |
| Coronary angiography | 320 mg I/mL | 50–250 mL |
| Peripheral angiography | 270 or 320 mg I/mL | varies by vessel |
| Intravenous urography | 270 mg I/mL | 50–100 mL |
| Venography | 270 mg I/mL | 50–100 mL per leg |
Intrathecal Administration (Myelography)
For myelography, Visipaque 270 mg I/mL is injected into the subarachnoid space. The typical volume is 10–15 mL for lumbar myelography and 10–12 mL for cervical or thoracic myelography. Intrathecal administration requires strict aseptic technique and must be performed only by experienced physicians. The total intrathecal dose should generally not exceed 3.0–3.5 grams of iodine to minimize the risk of neurotoxic side effects.
Children
In pediatric patients, the dose of Visipaque is calculated based on body weight. For intravenous CT enhancement, a typical dose is 1–2 mL/kg body weight for concentrations of 270–320 mg I/mL. The minimum effective dose should be used. For rectal administration in children (used in some gastrointestinal evaluations), diluted Visipaque may be administered as an enema. The volume and concentration are determined by the radiologist based on the child’s age and the clinical indication.
Elderly Patients
No specific dose adjustment is mandated for elderly patients. However, older adults are more likely to have reduced kidney function, cardiovascular disease, and other comorbidities that may increase the risk of adverse reactions to contrast media. Kidney function should always be assessed before contrast administration in elderly patients, and the minimum effective dose of Visipaque should be used. Adequate hydration before and after the procedure is particularly important in this population.
Oral Use
When used for gastrointestinal imaging (esophagus, stomach, or small bowel), Visipaque can be given as a drink, potentially diluted with water. The concentration and volume are determined by the radiologist. Oral iodinated contrast is particularly useful when barium sulfate is contraindicated, such as in cases of suspected gastrointestinal perforation, because iodinated contrast is absorbed from the peritoneal cavity, unlike barium, which can cause severe peritonitis if it leaks outside the bowel.
After Receiving Visipaque
After your procedure, you should:
- Stay hydrated: Drink plenty of fluids (water is best) in the hours following the procedure to help your kidneys excrete the contrast agent more quickly.
- Remain under observation: Stay at the imaging facility for at least 30 minutes after the procedure, and remain at the hospital or clinic for at least one hour. Most serious allergic reactions occur within the first 30 minutes, although delayed reactions can occur hours or days later.
- Report any symptoms: Tell your doctor or nurse immediately if you experience any unusual symptoms such as skin rash, difficulty breathing, swelling, dizziness, or nausea.
Because Visipaque is administered by trained healthcare professionals in controlled clinical settings, overdose is unlikely. In the rare event of accidental overdose, treatment is supportive with monitoring of vital signs and kidney function. Visipaque can be removed from the body by hemodialysis if necessary, although this is rarely required.
What Are the Side Effects of Visipaque?
Like all medicines, Visipaque can cause side effects, although not everyone will experience them. The type and frequency of side effects depend on the route of administration and the clinical context. Overall, Visipaque has a well-established safety profile based on decades of clinical use and extensive post-marketing surveillance data from millions of administrations worldwide.
Side effects of iodinated contrast media can be broadly divided into two categories: (1) allergic-like (hypersensitivity) reactions, which are unpredictable and can occur regardless of the dose, and (2) chemotoxic/osmotoxic reactions, which are dose-dependent and related to the physicochemical properties of the contrast agent. The iso-osmolar nature of Visipaque is designed to minimize the second category of reactions.
If you experience any of the following during or after receiving Visipaque, tell your doctor or nurse immediately: wheezing or difficulty breathing, chest tightness or pain, skin rash, hives, blisters on skin or in mouth, swelling of the face, lips, tongue or throat, dizziness or fainting. These may be signs of a serious allergic reaction. Such reactions may occur minutes to hours or even days after the procedure.
After Intravenous or Intra-arterial Injection
Uncommon
May affect up to 1 in 100 people
- Headache
- Nausea, vomiting
- Flushing (warmth in face)
- Kidney injury
- Sensation of warmth or heat
- Chest pain
Rare
May affect up to 1 in 1,000 people
- Dizziness
- Altered sensations (taste changes, smell changes, tingling, numbness, burning skin)
- Irregular heartbeat (arrhythmia)
- Low blood pressure (hypotension)
- Heart attack (myocardial infarction)
- Cough, sneezing
- Chills, fever, feeling cold
- Pain and local reactions at injection site
- General discomfort (malaise)
Very Rare
May affect up to 1 in 10,000 people
- Agitation, anxiety
- Stroke
- Fainting (syncope)
- Tremor (transient)
- Decreased skin sensation
- High blood pressure
- Difficulty breathing (dyspnea)
- Throat swelling
- Transient blindness or visual disturbances (including double vision, blurred vision)
- Swollen eyelids
- Abdominal pain, diarrhea
- Heart palpitations
- Cardiac arrest
- Transient memory loss
- Weakness, fatigue
- Back pain
- Facial swelling or injection site swelling
- Excessive sweating
- Muscle spasms
Not Known
Frequency cannot be estimated from available data
- Confusion, coma
- Seizures (convulsions)
- Blood clots (thrombosis)
- Arterial spasm (including coronary artery spasm)
- Shock
- Decreased heart pumping function
- Vein pain and swelling (thrombophlebitis)
- Severe breathing difficulty (pulmonary edema, bronchospasm, respiratory arrest)
- Pancreatitis (acute or worsened)
- Swollen salivary glands (iodine parotitis)
- Overactive thyroid (hyperthyroidism) or underactive thyroid (hypothyroidism)
- Joint pain
- Encephalopathy (brain dysfunction) including memory loss, hallucinations, vision loss, seizures, coordination loss, one-sided paralysis, speech difficulties, and loss of consciousness
- Elevated blood creatinine (indicating impaired kidney function)
- Iodism (iodine toxicity)
After Intrathecal Injection (Myelography)
Uncommon
May affect up to 1 in 100 people
- Headache (may be severe and last for hours)
- Vomiting
Not Known
Frequency cannot be estimated from available data
- Dizziness, nausea, chills
- Pain at injection site
- Encephalopathy (including confusion, memory loss, hallucinations, vision changes, seizures, coordination loss, one-sided paralysis, speech difficulties, loss of consciousness)
- Muscle spasms
After Use in Body Cavities
Very Common (Hysterosalpingography)
May affect more than 1 in 10 people
- Abdominal pain
- Vaginal bleeding
Common (Body Cavities / Joints)
May affect up to 1 in 10 people
- Headache
- Nausea
- Elevated body temperature
- Pain at injection site (arthrography)
After Oral Use
Common
May affect up to 1 in 10 people
- Diarrhea
- Nausea
- Abdominal pain
Uncommon
May affect up to 1 in 100 people
- Vomiting
In rare cases, patients may experience transient encephalopathy during or shortly after contrast media administration. Symptoms can include confusion, disorientation, memory loss, hallucinations, visual disturbances or blindness, seizures, loss of coordination, one-sided weakness or paralysis, speech difficulties, and decreased consciousness. These symptoms are usually reversible within hours to days. If you notice any neurological symptoms during or after the procedure, inform your doctor immediately.
How Should Visipaque Be Stored?
Visipaque should be stored in its original outer carton to protect it from light, as exposure to light can degrade the product. The solution must not be frozen. If accidentally frozen, the product should be discarded as freezing can alter the physical and chemical properties of the formulation and potentially compromise its safety and efficacy.
For patient comfort during injection, Visipaque can be warmed to body temperature (37°C / 98.6°F) in a dedicated warming cabinet prior to use. The product may be stored at 37°C for up to one month before use. Warming the contrast agent to body temperature has been shown to reduce the sensation of cold during injection and may decrease the viscosity of the solution, making injection through fine catheters easier.
Do not use Visipaque after the expiration date printed on the label (after “EXP”). The expiration date refers to the last day of that month. Any unused portion of the solution should be discarded after the procedure, as Visipaque is a preservative-free, single-use product. Partially used vials or bottles should not be retained for later use due to the risk of microbial contamination.
Keep Visipaque out of the sight and reach of children. As a hospital or clinic-administered product, this medication is stored in the radiology department and not typically dispensed to patients for home use.
What Does Visipaque Contain?
Visipaque is available in two concentrations that differ in their iodine content:
| Parameter | Visipaque 270 | Visipaque 320 |
|---|---|---|
| Iodixanol concentration | 550 mg/mL | 652 mg/mL |
| Iodine concentration | 270 mg I/mL | 320 mg I/mL |
| Osmolality | ~290 mOsm/kg (iso-osmolar) | ~290 mOsm/kg (iso-osmolar) |
The inactive ingredients (excipients) in both concentrations are:
- Trometamol (tromethamine): A buffering agent that helps maintain the pH of the solution
- Sodium chloride: Added to adjust the osmolality and maintain isotonicity
- Calcium chloride dihydrate: Included to maintain calcium levels and reduce cardiac effects
- Sodium calcium edetate (anhydrous): A stabilizing agent that chelates trace metal impurities
- Hydrochloric acid: Used for pH adjustment
- Water for injections: The solvent
Visipaque is a clear, colorless to slightly yellow, sterile aqueous solution. It is supplied in glass vials and polypropylene bottles (USB – Universal Spike Bottle) in various sizes ranging from 20 mL to 500 mL. Not all pack sizes may be marketed in all countries.
The marketing authorization holder is GE Healthcare AS, Oslo, Norway. Manufacturing takes place at GE Healthcare AS in Oslo, Norway, and at GE Healthcare Ireland Limited in Carrigtohill, Co. Cork, Ireland.
Frequently Asked Questions About Visipaque
Most patients experience a transient sensation of warmth that spreads through the body during the injection of Visipaque. This is a normal and expected effect of intravenous contrast administration and typically lasts only 15–30 seconds. Some patients describe a warm or flushing feeling in the chest, abdomen, or groin area. A metallic taste in the mouth may also occur briefly. Because Visipaque is iso-osmolar (matching the osmolality of blood), these sensations tend to be milder compared with older, higher-osmolality contrast agents. Pain at the injection site is uncommon. If you experience any severe or persistent symptoms, inform the healthcare staff immediately.
Visipaque is eliminated almost entirely by the kidneys. In patients with normal kidney function, approximately 97% of the injected dose is excreted unchanged in the urine within 24 hours. The elimination half-life is approximately 2 hours, meaning that half of the contrast agent is cleared from the blood in about 2 hours. In patients with impaired kidney function, the elimination is slower and may take several days. This is why adequate hydration after the procedure is important—it helps the kidneys flush the contrast agent out more efficiently. Visipaque is not metabolized by the liver and does not accumulate in any specific organ.
A common misconception is that patients allergic to “iodine” (e.g., seafood allergy or povidone-iodine skin allergy) cannot receive iodinated contrast media. In fact, allergic reactions to contrast media are not caused by the iodine element itself but by the overall molecular structure of the contrast agent. Having a shellfish allergy does not specifically increase the risk of a contrast reaction beyond the general increased risk seen in patients with any significant allergy. However, patients who have had a previous allergic reaction to an iodinated contrast agent are at genuinely increased risk (5–6 times) of another reaction and should inform their doctor before the procedure. Premedication with corticosteroids and antihistamines may be recommended.
Yes, iodinated contrast media including Visipaque can affect thyroid function. The iodine load from a single contrast-enhanced imaging study far exceeds the normal daily iodine intake and can be taken up by the thyroid gland. In most patients with normal thyroid function, this causes no clinical problem. However, in patients with subclinical hyperthyroidism, multinodular goiter, or Graves’ disease, the excess iodine can trigger overt hyperthyroidism (known as the Jod-Basedow effect). Conversely, in some patients, particularly those with Hashimoto’s thyroiditis, the iodine load can temporarily suppress thyroid function (the Wolff-Chaikoff effect). If you have any thyroid condition, inform your doctor before the procedure. Thyroid function tests should not be performed for several weeks after contrast administration, as results may be unreliable.
Preparation depends on the specific imaging procedure. General recommendations include: (1) Stay well hydrated by drinking plenty of water in the hours before the procedure, as this helps protect the kidneys. (2) Inform your doctor about all medications you are taking, especially metformin, beta-blockers, and any nephrotoxic drugs. (3) Tell your doctor about any allergies, asthma, or previous reactions to contrast media. (4) Mention any kidney or thyroid problems. (5) Follow any specific fasting instructions given by your healthcare facility—some procedures require you to fast for a few hours beforehand, while others do not. (6) If you are having an intrathecal (myelography) procedure, your doctor may advise discontinuing certain medications that lower the seizure threshold. Your healthcare team will provide specific instructions tailored to your procedure.
The key difference is that Visipaque is the only iso-osmolar contrast medium (IOCM) available. Other modern contrast agents (such as iohexol, iopamidol, ioversol, and iopromide) are classified as low-osmolar contrast media (LOCM), meaning their osmolality is 2–3 times higher than blood. The iso-osmolar property of Visipaque means it causes less osmotic stress when injected, which may result in less pain during injection, fewer hemodynamic disturbances, and potentially reduced risk of contrast-induced nephropathy in certain high-risk patient populations (such as those with pre-existing chronic kidney disease). However, for most patients with normal kidney function, the clinical differences between IOCM and LOCM are small, and both categories are considered safe and effective.
References
- European Medicines Agency (EMA). Visipaque – Summary of Product Characteristics. Last updated 2024. Available at: www.ema.europa.eu
- American College of Radiology (ACR). ACR Manual on Contrast Media. Version 2024. ACR Contrast Manual
- European Society of Urogenital Radiology (ESUR). ESUR Guidelines on Contrast Agents, Version 10.0. 2023. www.esur.org
- Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348(6):491–499. doi:10.1056/NEJMoa021833
- McCullough PA, Choi JP, Feghali GA, et al. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2016;68(13):1465–1473. doi:10.1016/j.jacc.2016.05.099
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023. www.who.int
- Thomsen HS, Morcos SK, Barrett BJ. Contrast-induced nephropathy: the wheel has turned 360 degrees. Acta Radiol. 2008;49(6):646–657. doi:10.1080/02841850801991999
- Royal College of Radiologists. Standards for intravascular contrast agent administration to adult patients. 3rd edition. 2024. www.rcr.ac.uk
- Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2020;294(3):660–668. doi:10.1148/radiol.2019192094
- Lee SY, Rhee CM, Leung AM, et al. A review: radiographic iodinated contrast media-induced thyroid dysfunction. J Clin Endocrinol Metab. 2015;100(2):376–383. doi:10.1210/jc.2014-3292
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Radiology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel of physicians reviewing according to international guidelines
Evidence Standard
Level 1A – Based on systematic reviews, meta-analyses of RCTs, and international radiology guidelines (ACR, ESUR)
Guideline Adherence
WHO, EMA, FDA, ACR Manual on Contrast Media, ESUR Contrast Agent Guidelines, Royal College of Radiologists
This article was last medically reviewed on . All content is based on current evidence-based guidelines and peer-reviewed research. iMedic receives no commercial funding and has no conflicts of interest.